← Back to home

RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS

Clinical trials for RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS trials appear

Sign up with your email to follow new studies for RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Targeted drug combo tested for Hard-to-Treat rare cancers

Disease control Recruiting now

This study is testing how well a combination of two targeted drugs works for people with rare, advanced cancers that have a specific genetic change (BRAF V600E mutation). It is open to both adults and children (age 1+) who have not been treated with these specific drugs before. T…

Matched conditions: RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS

Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS

Get alerted when new RARE UNRESECTABLE OR METASTATIC BRAF V600E MUTATION-POSITIVE SOLID TUMORS trials appear

Targeted drug combo tested for Hard-to-Treat rare cancers